ProCE Banner Activity

CE / CME

Transforming Modern Care in NSCLC: Navigating Advances in New and Emerging Biomarkers to Guide Precision Treatment Decisions

Multimedia
In this on-demand webcast from a live symposium, expert faculty discuss best practices for oncologists and pathologists in using biomarkers to guide current optimal treatment of patients with NSCLC and provide a look ahead at emerging biomarkers that may soon change practice.

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

ABPath MOC : maximum of {0:0.0#} Lifelong Learning (Part II) and Self-Assessment Module (SAM) point(s)

Released: May 21, 2021

Expiration: May 20, 2022

No longer available for credit.

Share

Faculty

Matthew Gubens

Matthew Gubens, MD, MS

Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

Lauren L. Ritterhouse

Lauren L. Ritterhouse, MD

Assistant Professor
Department of Pathology
Harvard Medical School
Associate Director
Center for Integrated Diagnostics
Department of Pathology
Massachusetts General Hospital
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Janssen administered by Scientific Affairs

Target Audience

This program is intended for oncologists, pathologists, and other healthcare providers who care for patients with lung cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Apply new and emerging predictive biomarkers to guide precision treatment decisions in patients with NSCLC
  • Discuss the practical aspects of biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays and other nuances
  • Evaluate the available next-generation sequencing and comprehensive genomic profiling diagnostic assays
  • Summarize the available data and expert recommendations to determine which biomarkers should be tested in your patients with lung cancer
  • Evaluate the available next-generation sequencing and comprehensive genomic profiling diagnostic assays
  • Identify best practices and strategies for interdisciplinary collaboration/coordination among pathologists and oncologists regarding cancer biomarker testing and interpretation of results to guide clinical decisions

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose any relevant conflict of interest (COI) they may have as related to the content of this activity. All identified COI are thoroughly vetted and resolved according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME/CE activity:

Faculty Disclosure

Primary Author

Matthew Gubens, MD, MS

Associate Professor
Thoracic Oncology
University of California, San Francisco
San Francisco, California

Matthew Gubens, MD, MS, has disclosed that he has received consulting fees from AstraZeneca, Beyond Spring, Bristol-Myers Squibb, Inivata, and Sanofi and funds for research support from Amgen, Celgene, Johnson & Johnson, Merck, Novartis, OncoMed, Roche, and Trizell.

Lauren L. Ritterhouse, MD

Assistant Professor
Department of Pathology
Harvard Medical School
Associate Director
Center for Integrated Diagnostics
Department of Pathology
Massachusetts General Hospital
Boston, Massachusetts

Lauren L. Ritterhouse, MD, has disclosed that she has received consulting fees from Amgen, Loxo Oncology, Merck, and Nuprobe.

Staff Disclosure

Staff

Jason J. Everly, PharmD

Jason Everly, PharmD, BCOP, CHCP, has no relevant conflicts of interest to report.

Terrence Fagan,

Associate Scientific Director

Terrence Fagan has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley, PhD, has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 Lifelong Learning points in the American Board of Pathology’s Maintenance of Certification (MOC) Program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting ABPath Continuing Certification (formerly Maintenance of Certification or MOC) credit.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from May 21, 2021, through May 20, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to improve the knowledge, competence, and performance of learners to assess new and emerging biomarkers and to plan individualized treatment for patients with lung cancer.